Researchers validate molecular signature to predict radiation therapy benefit

August 16, 2012

Researchers at Moffitt Cancer Center, working with colleagues in Sweden, the Netherlands and Puerto Rico, have validated a radiosensitivity molecular signature that can lead to better radiation therapy decisions for treating patients with breast cancer.

The results appeared in a recent issue of , a publication of the American Association for Cancer Research.

The study examined patients with who had been treated with radiation therapy and demonstrated that a radiosensitivity molecular signature (RSI) could predict clinical outcomes exclusively in patients treated with radiation therapy. The radiosensitivity molecular signature (RSI) used by the research team had previously been tested and validated for rectal, esophageal, and head and neck cancers. The technology, which identifies radiosensitivity and radioresistance, opens the door to biologically guided radiation therapy and offers the potential for better outcomes.

"Developing a radiosensitivity predictive assay has been a goal of radiation biology for decades," said Javier F. Torres-Roca, M.D., member of the Experimental Therapeutics program at Moffitt. "This effort supports the emphasis on personalized medicine, where the goal is to use molecular signatures to guide therapeutic decisions."

According to Torres-Roca, approximately 60 percent of all cancer patients receive radiation therapy during their treatment. Yet until now, no molecular diagnostic or biomarker of radiosensitivity had been developed to predict its benefit.

The radiosensitivity molecular signature was developed based on for 10 specific genes and a linear regression algorithm. RSI was developed in 48 cancer cell lines using a systems-biology strategy focused on identifying biomarkers for cellular radiosensitivity.

This study validated RSI's benefit when researchers found that radiosensitive had an improved five-year, relapse-free survival when compared to radioresistant patients.

"This study validated RSI in 503 patients in two independent data sets," Torres-Roca said. "We have validated RSI in five independent cohorts totaling 621 patients, so this latest validation study, to the best of our knowledge, makes this technology the most extensively validated molecular signature in radiation oncology."

The successful transition from applying the technology to cell lines to patient application also suggests that the biological basis of cellular radiosensitivity is conserved between cell lines and patients and also across epithelial tumors, Torres-Roca said.

"We propose that RSI is a predictive biomarker of therapeutic benefit for patients with breast cancer," Torres-Roca said. "This novel biomarker provides an opportunity to integrate individual tumor biology with clinical decision-making in radiation oncology."

Explore further: Radiation plus chemotherapy provides long-term positive results for head and neck cancer patients

Related Stories

Radiation plus chemotherapy provides long-term positive results for head and neck cancer patients

January 26, 2012
A select subgroup of advanced head and neck cancer patients treated with radiation therapy plus the chemotherapy drug cisplatin had more positive outcomes than patients treated with radiation therapy alone and continued to ...

Researchers find malignancy-risk gene signature for early-stage non-small cell lung cancer

January 6, 2012
A malignancy-risk gene signature developed for breast cancer has been found to have predictive and prognostic value for patients with early stage non-small cell lung cancer. The advancement was made by researchers at Moffitt ...

Recommended for you

Clinical trial suggests new cell therapy for relapsed leukemia patients

November 20, 2017
A significant proportion of children and young adults with treatment-resistant B-cell leukemia who participated in a small study achieved remission with the help of a new form of gene therapy, according to researchers at ...

Researchers discover a new target for 'triple-negative' breast cancer

November 20, 2017
So-called "triple-negative" breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities.

Study reveals new mechanism used by cancer cells to disarm attacking immune cells

November 20, 2017
A new study by researchers at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (OSUCCC - James) identifies a substance released by pancreatic cancer cells that protects ...

Cell-weighing method could help doctors choose cancer drugs

November 20, 2017
Doctors have many drugs available to treat multiple myeloma, a type of blood cancer. However, there is no way to predict, by genetic markers or other means, how a patient will respond to a particular drug. This can lead to ...

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.